

Serial No.: 09/925,778  
Group Art Unit No.: 1651

**Amendments to the Specification:**

Please add the following new section heading and new paragraph at page 1, after the title and before the section "FIELD OF THE INVENTION":

**RELATED APPLICATIONS**

This application is the National Stage of International Application No. PCT/US01/24950, filed August 9, 2001, which claims the benefit of Provisional Application No. 60/223909, filed August 9, 2000.

Please replace the paragraph beginning at page 22, line 17, which starts with "*Helicobacter pylori* (herein "*H. pylori*") bacteria infect the", with the following amended paragraph:

*Helicobacter pylori* (herein "*H. pylori*") bacteria infect the stomachs of over one-third of the world's population causing stomach cancer, ulcers, and gastritis (International Agency for Research on Cancer (IARC). (1994) *Schistosomes, Liver Flukes and Helicobacter Pylori*. IARC, 1994, Lyon, France). (International Agency for Research on Cancer, Lyon, France, <http://www.uicc.ch/ecp/ecp2904.htm>). Moreover, the International Agency for Research on Cancer recently recognized a cause-and-effect relationship between *H. pylori* and gastric adenocarcinoma, classifying the bacterium as a Group I (definite) carcinogen. Preferred antimicrobial compounds of the invention (agonists and antagonists of DXR polypeptides and/or polynucleotides) found using screens provided by the invention, or known in the art, particularly narrow-spectrum antibiotics, should be useful in the treatment of *H. pylori* infection. Such treatment should decrease the advent of *H. pylori*-induced cancers, such as gastrointestinal carcinoma. Such treatment should also prevent, inhibit and/or cure gastric ulcers and gastritis.